AIM ImmunoTech Inks Pancreatic Cancer Clinical Research Deals With AstraZeneca, Erasmus
LONDON (dpa-AFX) - Immuno-pharma company AIM ImmunoTech Inc. (AIM) announced Tuesday it has entered into an external sponsored collaborative clinical…
0,181€
Echtzeit-Aktienkurs AIM Immunotech Inc.
Bid:
Ask:
Nachrichten zur AIM Immunotech Inc. Aktie
Form 8-K AIM ImmunoTech Inc. For: Jan 13
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
Research collaboration will evaluate the potential of AIMs Ampligen® (rintatolimod) in combination with AstraZenecas Imfinzi (durvalumab) for the treatment of…